Galectin Therapeutics reported $17.12M in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Bristol Myers Squibb BMY:US USD 26.8B 3.39B
Galectin Therapeutics GALT:US USD 17.12M 8.66M
Gilead Sciences GILD:US USD 13.9B 723M
Idera Pharmaceuticals IDRA:US USD 30.07M 4.48M
Intercept Pharmaceuticals ICPT:US USD 545.37M 58.36M
Regulus Therapeutics RGLS:US USD 49.37M 2.02M
Vital Therapies VTL:US USD 86.65M 18.11M
YTE INCY:US USD 3.82B 195.27M